JUVÉDERM™ Ultra and JUVÉDERM™ Ultra Plus
The JUVÉDERM™ dermal filler family of products, approved by the U.S. Food and Drug Administration in 2006, is the next generation in hyaluronic acid dermal fillers that provide a smooth, long-lasting correction of moderate to severe facial wrinkles and folds.
JUVÉDERM™ is the first smooth consistency gel formulation and is clinically proven to last up to one year. JUVÉDERM™ is developed using the proprietary HYLACROSS™ technology, an advanced manufacturing process that results in a malleable, smooth gel that flows easily into the skin and creates a smooth, natural look and feel. All other hyaluronic acid dermal fillers currently on the market use a granular consistency gel. These granules can be seen under 2.4x magnification when compared to the smooth consistency gel of the JUVÉDERM™ dermal filler family of products.
To provide physicians with the flexibility to tailor each treatment to the specific needs of the patient, there are two formulations of JUVÉDERM™. Product formulations include: JUVÉDERM™ Ultra, a highly cross-linked formulation for more versatility in contouring and volumizing of facial wrinkles and folds; and JUVÉDERM™ Ultra Plus, a more highly cross-linked and thicker gel for volumizing and correction of deeper folds and wrinkles. Ask you doctor if JUVÉDERM™ is right for you.
Important Safety Information
In the United States, JUVÉDERM™ injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) and is generally well tolerated. The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness, firmness, lumps/bumps, and bruising. Exposure of the treated area to excessive sun and extreme cold weather should be minimized until any initial swelling and redness have resolved. If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM™ injectable gel, there is a possible risk of an inflammatory reaction at the treatment site.
Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. You should inform your physician before treatment if you are using these types of substances. As with all skin-injection procedures, there is a risk of infection. JUVÉDERM™ injectable gel should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body's immune response, as there may be an increased risk of infection. The safety of JUVÉDERM™ injectable gel in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied.
JUVÉDERM™ injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM™ injectable gel should not be used in patients with a history of allergies to Gram-positive bacterial proteins. The safety of JUVÉDERM™ injectable gel for use during pregnancy, in breastfeeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM™ injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies. For full risk information, please visit www.juvederm.com or call the Allergan Product Support line at 1-877-345-5372.